Celldex Therapeutics (STU:TCE2) Accumulated Depreciation : €0.00 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Celldex Therapeutics Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Celldex Therapeutics's quarterly accumulated depreciation increased from Sep. 2023 (€0.00 Mil) to Dec. 2023 (€-20.53 Mil) but then stayed the same from Dec. 2023 (€-20.53 Mil) to Mar. 2024 (€0.00 Mil).

Celldex Therapeutics's annual accumulated depreciation increased from Dec. 2021 (€-18.70 Mil) to Dec. 2022 (€-20.42 Mil) and increased from Dec. 2022 (€-20.42 Mil) to Dec. 2023 (€-20.53 Mil).

Celldex Therapeutics Accumulated Depreciation Historical Data

The historical data trend for Celldex Therapeutics's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celldex Therapeutics Accumulated Depreciation Chart

Celldex Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated Depreciation

Get a 7-Day Free Trial

-25.56

-17.46

-18.70

-20.42

-20.53

Celldex Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accumulated Depreciation	Get a 7-Day Free Trial															-	-	-	-20.53	-

Celldex Therapeutics Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

Celldex Therapeutics Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Celldex Therapeutics's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

Celldex Therapeutics (STU:TCE2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (STU:TCE2) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

CLDX:USA

Address

53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827

Website

https://www.celldex.com

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Celldex Therapeutics (STU:TCE2) Headlines

No Headlines